JP2008534609A - Ｈｓｐ９０阻害剤としてのアルキニルピロロピリミジンおよび関連類似体 - Google Patents

Ｈｓｐ９０阻害剤としてのアルキニルピロロピリミジンおよび関連類似体 Download PDF

Info

Publication number
JP2008534609A
JP2008534609A JP2008504412A JP2008504412A JP2008534609A JP 2008534609 A JP2008534609 A JP 2008534609A JP 2008504412 A JP2008504412 A JP 2008504412A JP 2008504412 A JP2008504412 A JP 2008504412A JP 2008534609 A JP2008534609 A JP 2008534609A
Authority
JP
Japan
Prior art keywords
group
compound
pharmaceutically acceptable
polymorph
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008504412A
Other languages
English (en)
Japanese (ja)
Inventor
スリニバス・アール・カシバトラ
マルコ・エイ・ビアモンテ
シ・ジャンドン
マーカス・エフ・ボーム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Conforma Therapeutics Corp
Original Assignee
Conforma Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37054161&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2008534609(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Conforma Therapeutics Corp filed Critical Conforma Therapeutics Corp
Publication of JP2008534609A publication Critical patent/JP2008534609A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
JP2008504412A 2005-03-30 2006-03-29 Ｈｓｐ９０阻害剤としてのアルキニルピロロピリミジンおよび関連類似体 Pending JP2008534609A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66689905P 2005-03-30 2005-03-30
PCT/US2006/011846 WO2006105372A2 (en) 2005-03-30 2006-03-29 Alkynyl pyrrolopyrimidines and related analogs as hsp90-inhibitors

Publications (1)

Publication Number Publication Date
JP2008534609A true JP2008534609A (ja) 2008-08-28

Family

ID=37054161

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008504412A Pending JP2008534609A (ja) 2005-03-30 2006-03-29 Ｈｓｐ９０阻害剤としてのアルキニルピロロピリミジンおよび関連類似体

Country Status (15)

Country Link
US (2) US7544672B2 (US07544672-20090609-C00134.png)
EP (1) EP1869027A4 (US07544672-20090609-C00134.png)
JP (1) JP2008534609A (US07544672-20090609-C00134.png)
KR (1) KR20080004550A (US07544672-20090609-C00134.png)
CN (1) CN101180297A (US07544672-20090609-C00134.png)
AU (1) AU2006230447A1 (US07544672-20090609-C00134.png)
BR (1) BRPI0609509A2 (US07544672-20090609-C00134.png)
CA (1) CA2602257A1 (US07544672-20090609-C00134.png)
EA (1) EA013522B1 (US07544672-20090609-C00134.png)
IL (1) IL186270A (US07544672-20090609-C00134.png)
MX (1) MX2007011903A (US07544672-20090609-C00134.png)
NO (1) NO20075099L (US07544672-20090609-C00134.png)
NZ (1) NZ561939A (US07544672-20090609-C00134.png)
WO (1) WO2006105372A2 (US07544672-20090609-C00134.png)
ZA (1) ZA200708520B (US07544672-20090609-C00134.png)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012503655A (ja) * 2008-09-26 2012-02-09 インテリカイン， インコーポレイテッド 複素環キナーゼ阻害剤
JP2013509423A (ja) * 2009-10-29 2013-03-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｄｐｐ−１阻害剤として有用なアルキニル誘導体
JP2017512503A (ja) * 2014-03-30 2017-05-25 セフィエド 修飾シトシンポリヌクレオチドオリゴマーおよび方法
JP2017516494A (ja) * 2014-03-30 2017-06-22 セフィエド 修飾チミンポリヌクレオチドオリゴマーおよび方法

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ561939A (en) * 2005-03-30 2011-03-31 Conforma Therapeutics Corp Alkynyl pyrrolopyrimidines and related analogs as HSP90-inhibitors
AU2007226344A1 (en) * 2006-03-11 2007-09-20 Vernalis (R & D) Ltd. Pyrrolopyrimidine derivatives used as HSP90 inhibitors
WO2007131034A1 (en) * 2006-05-03 2007-11-15 The Regents Of The University Of Michigan Pyrimidone derivatives which are modulators of heat shock protein (hsp) 70
EP2038041A4 (en) 2006-05-12 2010-02-17 Myriad Genetics Inc THERAPEUTIC COMPOUNDS AND THEIR USE AGAINST CANCER
WO2008045529A1 (en) * 2006-10-12 2008-04-17 Serenex, Inc. Purine and pyrimidine derivatives for treatment of cancer and inflammatory diseases
CL2007002994A1 (es) * 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
FR2907453B1 (fr) 2006-10-24 2008-12-26 Sanofi Aventis Sa Nouveaux derives du fluorene,compositions les contenant et utilisation
RU2009132605A (ru) 2007-02-01 2011-03-10 Астразенека Аб (Se) Производные 5,6,7,8-тетрагидроптеридина в качестве ингибиторов hsp90
EA200970669A1 (ru) * 2007-02-06 2010-02-26 Пфайзер Инк. Производные 2-амино-5,7-дигидро-6н-пирроло[3,4-d]пиримидина в качестве ингибиторов hsp-90, предназначенные для лечения рака
WO2009030871A1 (en) * 2007-09-07 2009-03-12 Vernalis R & D Ltd Pyrrolopyrimidine derivatives having hsp90 inhibitory activity
LT5623B (lt) 2008-04-30 2010-01-25 Biotechnologijos Institutas, , 5-aril-4-(5-pakeistieji 2,4-dihidroksifenil)-1,2,3-tiadiazolai kaip hsp90 šaperono slopikliai ir tarpiniai junginiai jiems gauti
WO2010018481A1 (en) 2008-08-13 2010-02-18 Pfizer Inc. 2-amino pyrimidine compounds as potent hsp-90 inhibitors
GB0819102D0 (en) * 2008-10-17 2008-11-26 Chroma Therapeutics Ltd Pyrrolo-pyrimidine compounds
GB0819105D0 (en) * 2008-10-17 2008-11-26 Chroma Therapeutics Ltd Pyrrolo-pyrimidine compounds
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
WO2014145576A2 (en) 2013-03-15 2014-09-18 Northwestern University Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer
KR102133569B1 (ko) * 2018-06-28 2020-07-13 한국과학기술연구원 신규한 피롤로[2,3-d]피리미딘-4-온 유도체 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
CN115192712B (zh) * 2022-07-05 2023-08-01 四川大学华西第二医院 Hsp抑制剂在制备胚胎神经系统畸形治疗的产品中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036075A2 (en) * 2000-11-02 2002-05-10 Sloan-Kettering Institute For Cancer Research Small molecule compositions for binding to hsp90
WO2003037860A2 (en) * 2001-10-30 2003-05-08 Conforma Therapeutics Corporation Purine analogs having hsp90-inhibiting activity
WO2005021552A1 (en) * 2003-08-29 2005-03-10 Vernalis (Cambridge) Ltd Pyrimidothiophene compounds
JP2007505933A (ja) * 2003-09-18 2007-03-15 コンフォーマ・セラピューティクス・コーポレイション Ｈｓｐ９０インヒビターとしての新規なヘテロ環化合物

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3595955A (en) 1969-03-26 1971-07-27 Upjohn Co Geldanamycin and process for producing same
US4261989A (en) 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
IL64501A (en) 1980-12-22 1985-07-31 Astra Laekemedel Ab 9-substituted 4-hydroxybutyl guanine derivatives,their preparation and antiviral use
US4533254A (en) 1981-04-17 1985-08-06 Biotechnology Development Corporation Apparatus for forming emulsions
US4699877A (en) 1982-11-04 1987-10-13 The Regents Of The University Of California Methods and compositions for detecting human tumors
US4921859A (en) 1983-10-31 1990-05-01 Warner-Lambert Company Purine derivatives
US5098906A (en) 1983-10-31 1992-03-24 Warner-Lambert Company Purine derivatives
US4806642A (en) 1984-10-05 1989-02-21 Warner-Lambert Company Purine derivatives
US4547573A (en) 1983-12-02 1985-10-15 Ici Pharma Process for preparing cephalosporin derivatives
EP0151528B1 (en) 1984-02-02 1990-07-04 Merck & Co. Inc. 5-(amino or substituted amino)-1,2,3-triazoles
US4748177A (en) 1984-03-26 1988-05-31 Warner-Lambert Company Guanine derivatives
US4617304A (en) 1984-04-10 1986-10-14 Merck & Co., Inc. Purine derivatives
IT1196261B (it) 1984-09-20 1988-11-16 Pierrel Spa Derivati nucleosidici e purinici 8-sostituiti
US4772606A (en) 1985-08-22 1988-09-20 Warner-Lambert Company Purine derivatives
IL76546A (en) 1984-10-12 1988-12-30 Warner Lambert Co 9-(heteroarylalkyl)-6-purine(thi)one derivatives,their preparation and pharmaceutical compositions containing them
JO1406B1 (en) 1984-11-02 1986-11-30 سميث كلاين اند فرينش لابوراتوريز ليمتد Chemical compounds
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
DE3650699T2 (de) 1985-03-15 1999-04-15 Antivirals Inc Immunotestmittel für Polynukleotid und Verfahren
DE3512194A1 (de) 1985-04-03 1986-10-09 Hoechst Ag, 6230 Frankfurt Ein neues ansamycin-antibiotikum, ein mikrobielles verfahren zu seiner herstellung und seine verwendung als arzneimittel
GB8515934D0 (en) 1985-06-24 1985-07-24 Janssen Pharmaceutica Nv (4-piperidinomethyl and-hetero)purines
US4918162A (en) 1986-05-06 1990-04-17 The Regents Of The University Of California Assays and antibodies for N-MYC proteins
US5002950A (en) 1986-10-24 1991-03-26 Warner-Lambert Co. 7-deazaguanines as immunomodulators
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5204353A (en) 1987-04-07 1993-04-20 Ciba-Geigy Corporation 3-benzyl-3H-1,2,3-triazolo[4,5-d]pyrimidines, compositions thereof, and method of treating epilepsy therewith
SE8801729D0 (sv) 1988-05-06 1988-05-06 Astra Ab Purine derivatives for use in therapy
US4923885A (en) 1988-08-19 1990-05-08 Merck & Co., Inc. 5-amino-1-(4-naphthoylbenzyl)-1,2,3-triazole-4-carboxamides and analogs as antiproliferative agents
EP0363320A3 (de) 1988-10-06 1991-11-21 Ciba-Geigy Ag Substituierte 9H-Purine
US5332744A (en) 1989-05-30 1994-07-26 Merck & Co., Inc. Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
DE69116750T2 (de) 1990-07-04 1996-11-14 Merrell Dow Pharma 9-Purinyl-Phosphonsäurederivate
GB9020931D0 (en) 1990-09-26 1990-11-07 Wellcome Found Heterocyclic compounds
DE69230349T2 (de) 1991-03-05 2000-07-27 Ajinomoto Kk Cyclopropanderivat
WO1992021032A1 (en) 1991-05-24 1992-11-26 The Regents Of The University Of California Methods for the detection of bcr-abl and abnormal abl proteins in leukemia patients
US6025126A (en) 1991-10-28 2000-02-15 Arch Development Corporation Methods and compositions for the detection of chromosomal aberrations
HU9401936D0 (en) 1992-01-06 1994-09-28 Pfizer Process and uses for 4,5-diohydrogeldanamycin and its hydroquinone
CA2093403C (en) 1992-04-08 1999-08-10 Fumio Suzuki Therapeutic agent for parkinson's disease
JPH0680670A (ja) 1992-09-03 1994-03-22 Ajinomoto Co Inc シクロプロパン誘導体及びその製造法
GB9226879D0 (en) 1992-12-23 1993-02-17 Iaf Biochem Int Anti-viral compounds
US6444656B1 (en) 1992-12-23 2002-09-03 Biochem Pharma, Inc. Antiviral phosphonate nucleotides
US6005107A (en) 1992-12-23 1999-12-21 Biochem Pharma, Inc. Antiviral compounds
US5387584A (en) 1993-04-07 1995-02-07 Pfizer Inc. Bicyclic ansamycins
US5602156A (en) 1993-09-17 1997-02-11 The United States Of America As Represented By The Department Of Health And Human Services Method for inhibiting metalloproteinase expression
US5744492A (en) 1993-09-17 1998-04-28 United States Of America Method for inhibiting angiogenesis
GB9402161D0 (en) 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
JP3769737B2 (ja) 1994-03-30 2006-04-26 味の素株式会社 シクロプロパン誘導体及びその製造法
US5932566A (en) 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
US5994361A (en) 1994-06-22 1999-11-30 Biochem Pharma Substituted purinyl derivatives with immunomodulating activity
US5525606A (en) 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
JPH0841035A (ja) 1994-08-05 1996-02-13 Ajinomoto Co Inc シクロプロパン誘導体及びその製造法
US5846749A (en) 1994-10-12 1998-12-08 The Regents Of The University Of California Quantitative measurement of tissue protein identified by immunohistochemistry and standardized protein determination
JPH08208687A (ja) 1994-11-25 1996-08-13 Sankyo Co Ltd グリセリルオリゴヌクレオチド
US5656629A (en) 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
US6177460B1 (en) 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
JPH0920776A (ja) 1995-06-30 1997-01-21 Nippon Paper Ind Co Ltd 新規なプリンヌクレオシド誘導体、その製造方法及びその誘導体を有効成分とする抗ウイルス剤
JPH09169758A (ja) 1995-10-18 1997-06-30 Nippon Paper Ind Co Ltd 新規なプリンヌクレオシド誘導体、その製造方法、及びそれを用いた抗ウイルス剤
JPH1025294A (ja) 1996-03-26 1998-01-27 Akira Matsuda 縮合ヘテロ環誘導体、その製造法及びそれを含有する悪性腫瘍治療剤
AU698419B2 (en) 1996-07-03 1998-10-29 Dainippon Sumitomo Pharma Co., Ltd. A novel purine derivative
US6723727B1 (en) 1996-12-20 2004-04-20 Hoechst Aktiengesellschaft Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them
WO1998039344A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
US5861503A (en) 1997-04-30 1999-01-19 The Regents Of The University Of California Process for producing 8-fluoropurines
JP4903922B2 (ja) 1997-05-14 2012-03-28 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 選択された蛋白質を分解する複合化合物
CN1268137A (zh) 1997-07-03 2000-09-27 杜邦药品公司 治疗神经失调的咪唑并嘧啶和咪唑并吡啶
EP1017394B1 (en) 1997-07-12 2005-12-07 Cancer Research Technology Limited Cyclin dependent kinase inhibiting purine derivatives
AUPO912997A0 (en) 1997-09-11 1997-10-02 Commonwealth Scientific And Industrial Research Organisation Antiviral agents
WO1999016465A1 (en) 1997-09-30 1999-04-08 Beth Israel Deaconess Medical Center Method for inhibiting tumor angiogenesis in a living subject
US5968921A (en) 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
DE69824632T2 (de) 1997-11-12 2005-06-09 Mitsubishi Chemical Corp. Purinderivate und medikamente, welche dieselben als aktiven bestandteil enthalten
TW572758B (en) 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
WO1999051223A1 (en) 1998-04-03 1999-10-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
SI20022A (sl) 1998-07-29 2000-02-29 Kemijski inštitut Alkilno substituirani purinovi derivati in njihova priprava
JP2000072773A (ja) 1998-08-28 2000-03-07 Zeria Pharmaceut Co Ltd プリン誘導体
JP2000072733A (ja) 1998-08-31 2000-03-07 Kanebo Ltd アミド化合物の製造法
US6140374A (en) 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
JP2002532535A (ja) 1998-12-22 2002-10-02 アメリカ合衆国 水不溶性薬剤送達システム
JP2002539076A (ja) 1999-01-06 2002-11-19 ユニバーシティ・オブ・サザン・カリフォルニア 新脈管形成抑制のための方法および組成物
DK1150982T3 (da) 1999-02-01 2005-12-27 Cv Therapeutics Inc Purininhibitorer af cylkineafhængig kinase 2 og 1kB-alfa
FR2790702B1 (fr) 1999-03-08 2001-07-20 Sidel Sa Unite de moulage et machine d'extrusion-soufflage munie d'une telle unite
US6174875B1 (en) 1999-04-01 2001-01-16 University Of Pittsburgh Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
WO2000061578A1 (en) 1999-04-09 2000-10-19 Sloan-Kettering Institute For Cancer Research Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases
WO2000068230A1 (en) 1999-05-05 2000-11-16 Darwin Discovery Limited 9-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,9-dihydropurin-6-one derivatives as pde7 inhibitors
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
GB0100621D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VI
GB0100624D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
MY141789A (en) 2001-01-19 2010-06-30 Lg Chem Investment Ltd Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same.
US20020156277A1 (en) 2001-04-20 2002-10-24 Fick David B. Synthesis and methods of use of purine analogues and derivatives
US20030022864A1 (en) 2001-04-24 2003-01-30 Ishaq Khalid S. 9-[(5-dihydroxyboryl)-pentyl] purines, useful as an inhibitor of inflammatory cytokines
US6962991B2 (en) 2001-09-12 2005-11-08 Epoch Biosciences, Inc. Process for the synthesis of pyrazolopyrimidines
JP2003113181A (ja) 2001-10-04 2003-04-18 Sumika Fine Chemicals Co Ltd ６−ハロプリンの製造方法
CN1688580A (zh) 2002-08-08 2005-10-26 记忆药物公司 作为磷酸二酯酶4抑制剂的2－三氟甲基－6－氨基嘌呤衍生物
GB0219746D0 (en) 2002-08-23 2002-10-02 Inst Of Ex Botany Ascr Azapurine derivatives
AU2003267145A1 (en) 2002-09-13 2004-04-30 Irm, Llc Highly specific modulators of gtpases for target validation
EP1546164A4 (en) 2002-09-26 2006-06-07 Lg Life Sciences Ltd (+) - TRANS-ISOMERS OF (1-PHOSPHONOMETHOXY-2-ALKYLCYCLOPROPYL) METHYL NUCLEOSIDE DERIVATIVES, METHOD FOR THE PRODUCTION OF STEREO-ISOMERS THEREOF, AND THE USE OF ANTIVIRAL AGENTS PRODUCED THEREOF
US7601694B2 (en) 2003-02-20 2009-10-13 New York University CLK-peptide and SLK-peptide
US7579332B2 (en) 2003-07-30 2009-08-25 Gilead Sciences, Inc. Nucleobase phosphonate analogs for antiviral treatment
US20050054614A1 (en) 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
WO2005016348A1 (en) 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
CN100475815C (zh) 2003-09-25 2009-04-08 詹森药业有限公司 抑制hiv复制的嘌呤衍生物
KR20050062944A (ko) 2003-12-19 2005-06-28 주식회사 엘지생명과학 디이소프로필((1-((2-아미노-6-클로로-9ｈ-퓨린-9-일)메틸)사이클로프로필)옥시)-메틸포스포네이트의 새로운 제조방법
KR20050062940A (ko) 2003-12-19 2005-06-28 주식회사 엘지생명과학 디이소프로필((1-((2-아미노-6-할로-9ｈ-퓨린-9-일)메틸)사이클로프로필)옥시)-메틸포스포네이트의 새로운 제조방법
WO2005067901A2 (en) 2004-01-08 2005-07-28 Michigan State University Methods for treating and preventing hypertension and hypertension-related disorders
TW200533358A (en) 2004-02-17 2005-10-16 Anadys Pharmaceuticals Inc Nucleoside phosphonate derivatives useful in the treatment of hiv infections
US20070225303A1 (en) 2004-03-26 2007-09-27 Haruhisa Ogita 8-Oxoadenine Compound
NZ561939A (en) 2005-03-30 2011-03-31 Conforma Therapeutics Corp Alkynyl pyrrolopyrimidines and related analogs as HSP90-inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036075A2 (en) * 2000-11-02 2002-05-10 Sloan-Kettering Institute For Cancer Research Small molecule compositions for binding to hsp90
WO2003037860A2 (en) * 2001-10-30 2003-05-08 Conforma Therapeutics Corporation Purine analogs having hsp90-inhibiting activity
WO2005021552A1 (en) * 2003-08-29 2005-03-10 Vernalis (Cambridge) Ltd Pyrimidothiophene compounds
JP2007505933A (ja) * 2003-09-18 2007-03-15 コンフォーマ・セラピューティクス・コーポレイション Ｈｓｐ９０インヒビターとしての新規なヘテロ環化合物

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012503655A (ja) * 2008-09-26 2012-02-09 インテリカイン， インコーポレイテッド 複素環キナーゼ阻害剤
JP2013509423A (ja) * 2009-10-29 2013-03-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｄｐｐ−１阻害剤として有用なアルキニル誘導体
JP2017512503A (ja) * 2014-03-30 2017-05-25 セフィエド 修飾シトシンポリヌクレオチドオリゴマーおよび方法
JP2017516494A (ja) * 2014-03-30 2017-06-22 セフィエド 修飾チミンポリヌクレオチドオリゴマーおよび方法

Also Published As

Publication number Publication date
NO20075099L (no) 2007-10-29
IL186270A (en) 2012-08-30
CN101180297A (zh) 2008-05-14
WO2006105372A3 (en) 2007-07-19
AU2006230447A1 (en) 2006-10-05
US20090318387A1 (en) 2009-12-24
EP1869027A2 (en) 2007-12-26
US8093229B2 (en) 2012-01-10
EA200702109A1 (ru) 2008-06-30
EP1869027A4 (en) 2010-06-23
CA2602257A1 (en) 2006-10-05
NZ561939A (en) 2011-03-31
WO2006105372A2 (en) 2006-10-05
ZA200708520B (en) 2008-10-29
US20060223797A1 (en) 2006-10-05
MX2007011903A (es) 2007-12-05
EA013522B1 (ru) 2010-06-30
KR20080004550A (ko) 2008-01-09
US7544672B2 (en) 2009-06-09
IL186270A0 (en) 2008-01-20
BRPI0609509A2 (pt) 2010-04-13

Similar Documents

Publication Publication Date Title
JP2008534609A (ja) Ｈｓｐ９０阻害剤としてのアルキニルピロロピリミジンおよび関連類似体
JP5820882B2 (ja) キナーゼインヒビターとしてのキノリン及びキノキサリン誘導体
US7138402B2 (en) Pyrrolopyrimidines and related analogs as HSP90-inhibitors
JP5524084B2 (ja) Ｈｓｐ９０阻害剤としてのオキシム誘導体
RU2468026C2 (ru) Производные пуринила и их применение в качестве модуляторов калиевых каналов
EA011815B1 (ru) Пирролопиразолы в качестве сильнодействующих ингибиторов киназы
JP2016513117A (ja) 過剰増殖性疾患を治療するためのｂｅｔタンパク質阻害剤としてのピロロ−およびピラゾロ−トリアゾロジアゼピン類
US20070253896A1 (en) 7,9-Dihydro-Purin-8-One and Related Analogs as HSP90-Inhibitors
JP2020504747A (ja) ベンズイミダゾール誘導体、調製方法およびそれらの使用
JP2008523103A (ja) Ｅｒｋプロテインキナーゼのピリミジンインヒビターおよびその使用
JP2016513118A (ja) ４−置換されたピロロ−およびピラゾロジアゼピン類
JP2009532375A (ja) キナーゼ阻害剤
JP4976394B2 (ja) 新規な高親和性のキノリンベースのキナーゼリガンド
JP2017515848A (ja) タンパク質脱アセチル化酵素阻害剤およびタンパク質脱アセチル化酵素−タンパク質キナーゼ二重阻害剤としての複素環式ヒドロキサム酸ならびにその使用方法
AU2016214492B2 (en) 2-phenyl-3H-imidazo[4,5-b]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ROR1activity
US7888380B2 (en) 1,2,4-Triazolylaminoaryl (heteroaryl) sulfonamide derivatives
JP2010540423A (ja) ピロロピリミジン化合物類
AU2018337138B2 (en) 2-substituted pyrazole amino-4-substituted amino-5-pyrimidine formamide compound, composition, and application thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090219

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20090224

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090917

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20111012

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111018

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120321